Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP005 study

D. Heudobler,L. Villanueva,Z. Lwin,H. C. Chung,C. Gomez-Roca, F. L. Munoz,E. Yanez,H. Senellart,M. Doherty,J. Garcia-Corbacho,A. E. Hendifar,C. Maurice-Dror,S. Gill,T. W. Kim,N. Penel,R. Ghori,P. Kubiak,F. Jin,K. Norwood,D. Graham

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 46|浏览13

暂无评分

摘要

321Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination with the programmed deat...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要